Clinical trial
Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease
NCT00224263 · Xuanwu Hospital, Beijing, Other · Completed
Key facts
| NCT number | NCT00224263 |
|---|---|
| Title | Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease Receiving Stable L-dopa/DCI |
| Lead sponsor | Xuanwu Hospital, Beijing, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | Lingzhi (Ganoderma) |
| Enrollment | 360 |
| Start date | Sep 1, 2005 |
| Completion | Feb 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Aug 16, 2011 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: